# RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

> **NCT00808067** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 5897 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** dabigatran dose 1
- **DRUG:** dabigatran dose 2

## Key facts

- **NCT ID:** NCT00808067
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 5897 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00808067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00808067, "RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00808067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*